New hope for advanced tumors: HRS-3802 enters human testing

NCT ID NCT06770569

Recruiting now Disease control Sponsor: Shandong Suncadia Medicine Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests a new drug called HRS-3802 in 100 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants will receive the drug alone and be closely monitored for side effects and tumor response.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS

Contacts and locations

Locations

Cancer Hospital Chinese Academy of Medical Sciences
RECRUITING

Beijing, Beijing Municipality, 100021, China
GenesisCare North Shore (Oncology)
ACTIVE_NOT_RECRUITING

Saint Leonards, New South Wales, 2065, Australia
GenesisCare St Andrews
ACTIVE_NOT_RECRUITING

Adelaide, South Australia, 5000, Australia
John Flynn Private Hospital
ACTIVE_NOT_RECRUITING

Tugun, Queensland, 4224, Australia
Macquarie University Hospital
ACTIVE_NOT_RECRUITING

Sydney, New South Wales, 2109, Australia
Peninsula and South Eastern Haematology & Oncology Group
ACTIVE_NOT_RECRUITING

Frankston, Victoria, 3199, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.